-The Hindu   Overdue commissioning of plant could be further delayed The Atomic Energy Regulatory Board (AERB) on Friday acknowledged that four valves were found defective during tests at the Kudankulam nuclear power plant in Tamil Nadu and said they were being replaced. In a press release, the Board also indicated that the long overdue commissioning of the plant could be further delayed as the new valves were again being put to the test....

-The Guardian Land rights not just issue for developing world as report shows public subsidies help a few firms 'grab' vast tracts of EU land Vast tracts of land in Europe are being "grabbed" by large companies, speculators, wealthy foreign buyers and pension funds in a similar way to in developing countries, according to a major new report. Chinese corporations, Middle Eastern sovereign wealth and hedge funds, as well as Russian oligarchs and...

-The Indian Express India is no insecure dictatorship junking international obligations for cheap populism. The highest court of the world's largest democracy has made a nuanced distinction between real innovation and marketing gimmickry. Yet, the Swiss pharmaceutical giant Novartis's response to the recent Supreme Court verdict in Novartis vs Union of India has been imperial in tone. The judgment "discourages innovative drug discovery", it claimed. It accused Indian law of lagging...

-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...

-Live Mint SC rejects Novartis's patent plea for Glivec, says it does not meet any standard of novelty or inventiveness In a landmark judgement, India's apex court rejected Swiss drug maker Novartis AG's legal challenge aimed at securing a patent for blockbuster anti-cancer drug imatinib mesylate, branded Glivec in the country. The verdict, which is seen as a setback to multinational pharmaceutical companies operating in India, may influence a rash of pending disputes...